Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.085
-0.085 (-7.26%)
Mar 31, 2025, 3:43 PM EDT - Market open
Silexion Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Silexion Therapeutics stock has a target of 5.00, which predicts an increase of 360.83% from the current stock price of 1.09.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Silexion Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $9 → $5 | Strong Buy | Maintains | $9 → $5 | +360.83% | Mar 20, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +729.49% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-11.52
from -81.80
EPS Next Year
-0.98
from -11.52
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | n/a | n/a | n/a |
| Avg | n/a | n/a | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -11.85 | -1.01 | -1.38 | |
| Avg | -11.52 | -0.98 | -1.34 | |
| Low | -11.06 | -0.94 | -1.28 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.